Illuminate PD1/PD-L1 Interactions: Explore immune checkpoint activation in situ
We are thrilled to introduce our new product Naveni™ PD1/PD-L1 Atto647N
Unlocking the potential of immune checkpoint inhibition therapy calls for precise patient stratification. While PD-L1 is a commonly used biomarker, its correlation with immunotherapy outcomes isn’t always linear. Addressing this challenge, Navinci presents Naveni™ PD1/PD-L1 Atto647N, the pioneering fluorescent assay for in situ detection of PD1/PD-L1 interactions.